Improving access to pain relief in India

Improving Appropriate Access and Availability of Opioids for Cancer-related Pain Control in India (IMPOP): bridging the gap between policy and practice - IMPOP

Status

Recruiting

Phases

Phase 1

Study type

Observational

Source

CTRI

Registry ID

CTRI/2021/04/033156

Enrollment

Registered

2021-04-27

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: Doctors nurses pharmacists service managers or other worker pertinent to opioid use for cancer related pain. Part of an Indian palliative care team where opioids are routinely used for cancer related pain Able and willing to give informed verbal recorded consent to interview Palliative care service self-reporting routine use of Morphine or other opioid annually for cancer related pain

Exclusion criteria

Exclusion criteria: Failure to meet inclusion criteria

Design outcomes

Primary

Measure	Time frame
Key findings from our analysis of the interview data within four areas relevant to Good Practice (procurement, storage, prescribing and dispensing) will be organized into a Handbook, highlighting important steps necessary for ensuring safe availability of opioids within services, including necessary regulatory processes for opioid licensing, through to appropriate prescribing and dispensed.Timepoint: 6 months following study data collection completion ( 31st July 2021)	—

Measure

Time frame

Key findings from our analysis of the interview data within four areas relevant to Good Practice (procurement, storage, prescribing and dispensing) will be organized into a Handbook, highlighting important steps necessary for ensuring safe availability of opioids within services, including necessary regulatory processes for opioid licensing, through to appropriate prescribing and dispensed.Timepoint: 6 months following study data collection completion ( 31st July 2021)

—

Secondary

Measure	Time frame
A provisional Handbook will be presented to all co-investigators and appropriate amendments made. Once the study team have agreed the content of this Handbook first draft, we will invite key stakeholders in cancer care across India and regionally known to the study team and participants, to an expert consensus workshop to refine the Handbook for wider circulation Once the Handbook has been finalised, we will hold a dissemination Workshop, to which key stakeholders will be invited.Timepoint: 1 year following study data collection completion (31st July 2021)	—

Measure

Time frame

A provisional Handbook will be presented to all co-investigators and appropriate amendments made. Once the study team have agreed the content of this Handbook first draft, we will invite key stakeholders in cancer care across India and regionally known to the study team and participants, to an expert consensus workshop to refine the Handbook for wider circulation Once the Handbook has been finalised, we will hold a dissemination Workshop, to which key stakeholders will be invited.Timepoint: 1 year following study data collection completion (31st July 2021)

—

Countries

India

Contacts

Public ContactDr Naveen Salins

Kasturba Medical College

naveensalins@gmail.com919969683669

Outcome results